Stay updated with breaking news from Works therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15. ....
SpringWorks Therapeutics drug for treating adult patients with a type of rare noncancerous soft-tissue tumor will be sold in the US at a list price of $29,000 for a 30-day supply. ....
SpringWorks Therapeutics drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said. ....
Biggest stock movers today: Carlyle Group, Zscaler and more (NASDAQ:SWTX) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.